What Is Selank and How Does It Work
Selank is a synthetic heptapeptide developed in Russia at the Institute of Molecular Genetics, structurally derived from tuftsin, a naturally occurring tetrapeptide with immunomodulatory activity. It was designed as an anxiolytic (anti-anxiety) compound with an added nootropic (cognitive-supportive) profile, and has been studied primarily as a research alternative to benzodiazepine-class anxiety medications, without the sedation and dependence risk historically associated with that drug class.
Selank's anxiolytic effect is attributed to several interacting pathways rather than a single receptor target. Proposed mechanisms in the research literature include positive allosteric modulation of GABA-A receptors, modulation of serotonin metabolism through effects on tryptophan hydroxylase expression, increased expression of brain-derived neurotrophic factor (BDNF), and inhibition of enkephalinase - the enzyme that breaks down the body's own enkephalin opioid peptides, prolonging their natural calming effect. This multi-pathway profile is the proposed basis for reports that Selank produces anxiolytic effects without the sedation, motor impairment, or dependence potential reported with benzodiazepines, though that comparison rests on a much smaller and less independently replicated evidence base.
Research Dosing
Dosing below reflects ranges reported in the published Russian clinical literature and conventions commonly cited in the research-peptide community, not personal medical guidance.
| Context | Dose | Frequency | Route |
|---|---|---|---|
| Common research-community protocol | 250–900mcg | 1–3× daily | Intranasal spray |
| Published GAD clinical study | Up to 2,700mcg/day | Daily, 14–21 day course | Intranasal spray |
Context: Most Selank research protocols use a cycling approach - commonly two to three weeks on followed by at least a week off - based on concern that continuous GABAergic stimulation could blunt its effect over time. This cycling convention is a common-sense precaution borrowed from other GABAergic compounds; it has not itself been formally tested in controlled Selank trials.
Regulatory Status
Selank is not an FDA-approved drug in the United States and has not undergone FDA review for safety or efficacy in any indication. Its regulatory standing is meaningfully different in Russia, where it was approved in 2009 as a prescription nasal spray for generalized anxiety disorder and related conditions, and where a body of Russian-language clinical and preclinical literature has accumulated since development began in the 1990s. In the US, products sold as "Selank" - including any product carried by research-chemical suppliers - are marketed for laboratory research use only, not for human consumption, and carry none of the FDA approval or compounding-pharmacy oversight that governs approved drugs. Consult a qualified healthcare provider before considering any peptide protocol.
What Research Shows
The most directly relevant clinical evidence comes from a Russian human trial evaluating Selank in patients with generalized anxiety disorder and neurasthenia, which reported anxiolytic effects alongside antiasthenic and mild psychostimulant effects without the sedation typically seen with benzodiazepine comparators.
This study was published in a Russian-language journal, and independent replication in peer-reviewed, placebo-controlled trials outside Russia remains limited. Most of the mechanistic work on GABA modulation, serotonin turnover, and BDNF expression referenced above comes from animal and in-vitro research rather than large human trials, so the evidence base should be weighed as preliminary relative to established, FDA-approved anxiolytic medications.